Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?

ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.

Gilead and Cartography enter deal to develop cancer therapies

Gilead and Cartography will develop treatments for triple-negative breast cancer and adenocarcinoma. Credit: JHVEPhoto / Shutterstock.com. Cartography Biosciences has announced a strategic partnership with Gilead

May 29, 2024

John Carroll on his cancer diagnosis; #ESMO’s biggest surprise; Lykos’ bad trip; Rate cuts, and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 22, 2024

Study links brisk walking to lower type 2 diabetes risk

A recent study in the British Journal of Sports Medicine reveals that brisk walking significantly reduces the risk of type 2 diabetes. The systematic review

December 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.